Faculty profile

David Uehling

Back to faculty

Assistant ProfessorUniversity of Toronto

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Latest papers

Discovery and development of potent and selective dual NUAK/MARK inhibitors as Hippo pathway modulators for the treatment of cancer.
European journal of medicinal chemistry · 2026
Structure-based discovery of sulfamoyl-ethyl-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidine amides and sulfonamides as potent B-Cell Lymphoma 6 (BCL6)-BTB inhibitors.
Bioorganic & medicinal chemistry letters · 2026
Cell-based and isoform-selective G protein-coupled receptor kinase assays for comprehensive inhibitor evaluation.
Communications biology · 2026

All 25 publications

25 publications.

Discovery and development of potent and selective dual NUAK/MARK inhibitors as Hippo pathway modulators for the treatment of cancer.

Smil D, Liu Y, Xin T, Kiyota T, Aman A, Grouleff J, Hoffer L, Joshi DC, Inanlou MR, Song S, Mao DYL, Ogunjimi AA, Pau V, Chini FD, Kurinov I, Zhang Y, Nguyen AT, Wrana JL, Sicheri F, Attisano L, Uehling D, Al-Awar R, Isaac MB

European journal of medicinal chemistry2026

DOI: 10.1016/j.ejmech.2026.118798 PMID: 41936796

Structure-based discovery of sulfamoyl-ethyl-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidine amides and sulfonamides as potent B-Cell Lymphoma 6 (BCL6)-BTB inhibitors.

Mamai A, Morshed MM, Prakesch M, Poda G, Subramanian P, Chau AM, Watson IDG, Joseph B, Wilson B, Morin JA, Marcellus R, Theriault B, Mohammed M, Abibi A, Chan M, Kiyota T, Aman A, Subramaniam R, Strathdee C, Winston J, O'Meara J, Kuntz D, Pomroy NC, Uehling D, Isaac M, Privé GG, Al-Awar R

Bioorganic & medicinal chemistry letters2026

DOI: 10.1016/j.bmcl.2025.130471 PMID: 41241078

Cell-based and isoform-selective G protein-coupled receptor kinase assays for comprehensive inhibitor evaluation.

Blum NK, Kiefer MC, Decker A, Klement L, Matthees ESF, Weitzel V, Nagel F, Joseph B, Drube J, Uehling D, Hoffmann C, Schulz S

Communications biology2026

DOI: 10.1038/s42003-026-09568-0 PMID: 41545717

OICR-41103 as a chemical probe for the DCAF1 WD40 domain.

Kimani SW, Noureldin M, Wilson B, Hoffer L, Green SR, Szewczyk MM, González-Álvarez H, Mohammed M, Chan M, Krausser C, Li ASM, Hajian T, Tucker S, Joshi D, Saraon P, Thériault B, Kim JS, Santhakumar V, Loppnau P, Li Y, Seitova A, Dong A, Kiyota T, Hammann T, Gehrtz P, Patel B, Rathod V, Vala A, Rout B, Jagodra P, Brown PJ, Aman A, Ramnauth J, Poda G, Uehling D, Arrowsmith CH, Barsyte-Lovejoy D, Marcellus R, Ackloo S, Mamai A, Al-Awar R, Halabelian L

Communications biology2025

DOI: 10.1038/s42003-025-08491-0 PMID: 40683980

Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity.

Mabanglo MF, Wilson B, Noureldin M, Kimani SW, Mamai A, Krausser C, González-Álvarez H, Srivastava S, Mohammed M, Hoffer L, Chan M, Avrumutsoae J, Li ASM, Hajian T, Tucker S, Green S, Szewczyk M, Barsyte-Lovejoy D, Santhakumar V, Ackloo S, Loppnau P, Li Y, Seitova A, Kiyota T, Wang JG, Privé GG, Kuntz DA, Patel B, Rathod V, Vala A, Rout B, Aman A, Poda G, Uehling D, Ramnauth J, Halabelian L, Marcellus R, Al-Awar R, Vedadi M

Nature communications2024

DOI: 10.1038/s41467-024-54500-x PMID: 39580491

Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation.

Mader MM, Rudolph J, Hartung IV, Uehling D, Workman P, Zuercher W

Cancer discovery2023

DOI: 10.1158/2159-8290.cd-23-0536 PMID: 37712569

Targeting tumour-associated macrophages in hodgkin lymphoma using engineered extracellular matrix-mimicking cryogels.

Bahlmann LC, Xue C, Chin AA, Skirzynska A, Lu J, Thériault B, Uehling D, Yerofeyeva Y, Peters R, Liu K, Chen J, Martel AL, Yaffe M, Al-Awar R, Goswami RS, Ylanko J, Andrews DW, Kuruvilla J, Laister RC, Shoichet MS

Biomaterials2023

DOI: 10.1016/j.biomaterials.2023.122121 PMID: 37075613

An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma

Adile AA, Bakhshinyan D, Suk Y, Uehling D, Saini M, Aman A, Magolan J, Subapanditha MK, McKenna D, Chokshi C

Journal of Neuro-Oncology20234 citations

DOI: 10.1007/s11060-023-04372-w

Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.

Sahin C, Magomedova L, Ferreira TAM, Liu J, Tiefenbach J, Alves PS, Queiroz FJG, Oliveira AS, Bhattacharyya M, Grouleff J, Nogueira PCN, Silveira ER, Moreira DC, Leite JRSA, Brand GD, Uehling D, Poda G, Krause H, Cummins CL, Romeiro LAS

Journal of medicinal chemistry2022

DOI: 10.1021/acs.jmedchem.1c01542 PMID: 35089724

The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia.

Edilova MI, Law JC, Zangiabadi S, Ting K, Mbanwi AN, Arruda A, Uehling D, Isaac M, Prakesch M, Al-Awar R, Minden MD, Abdul-Sater AA, Watts TH

Oncoimmunology2021

DOI: 10.1080/2162402x.2021.1943234 PMID: 34589290

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

David Uehling

Research

Latest papers

Discovery and development of potent and selective dual NUAK/MARK inhibitors as Hippo pathway modulators for the treatment of cancer.

Structure-based discovery of sulfamoyl-ethyl-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidine amides and sulfonamides as potent B-Cell Lymphoma 6 (BCL6)-BTB inhibitors.

Cell-based and isoform-selective G protein-coupled receptor kinase assays for comprehensive inhibitor evaluation.

OICR-41103 as a chemical probe for the DCAF1 WD40 domain.

Crystal structures of DCAF1-PROTAC-WDR5 ternary complexes provide insight into DCAF1 substrate specificity.

Which Small Molecule? Selecting Chemical Probes for Use in Cancer Research and Target Validation.

Targeting tumour-associated macrophages in hodgkin lymphoma using engineered extracellular matrix-mimicking cryogels.

An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma

Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.

The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia.

Frequent collaborators

Ahmed Aman

Brian Wilson

Frank Sicheri

Dalia Barsyte-Lovejoy

Eldad Zacksenhaus

Marianne Koritzinsky

Daniel Durocher

Martin Yaffe

Liliana Attisano

Henry Krause

Jakob Magolan

David Andrews

Jens Tiefenbach

Mikko Taipale

Jason Moffat

Martin Gleave

Marc Therrien

Samuel Weiss

Amina Zoubeidi

Adrian Sacher

John Kuruvilla